京新药业 (002020)

ZHEJIANG JINGXIN PHARMACEUTICAL Co., Ltd.

ASZ

Tags

CSI Share Buyback IndexGeneric DrugsChemical PharmaceuticalsEmployee Stock OwnershipBuyback PlansNew Social Security Fund HoldingsHigh-Performing StocksShenzhen ConnectTech 100 IndexSZSE Medicine Equal Weight IndexPharmaceutical IndexSina 100 IndexShenzhen A-Share Pharmaceutical IndexCSI All-share Pharmaceutical Sector IndexSZSE 700 IndexSHS Technology 100 IndexSZSE 1000 IndexHangzhou Bay Area IndexPhoenix 50 IndexSME Board Value IndexZhongchuang Value IndexMilitary PartsYangtze River Delta Economic ZoneFTSE Russell ConceptInsurance Heavy HoldingsSME Board Composite IndexSZSE Selected IndexSME Board Innovation IndexSZSE Pharmaceutical IndexCS Pharmaceutical TI IndexCSI 1000 IndexSME Board Low Volatility IndexPharmaceutical & Health 100 IndexZhongchuang Low Volatility IndexPharmaceutical 50 Strategy IndexCSI 1000 Growth Innovation IndexCICC 300 IndexZhongchuang 400 IndexCS Innovative Drugs IndexCR New Momentum IndexCSI 1000 Value IndexCSI 1000 Value Stable IndexZhejiang

K-Line Chart

No K-line data available

Company NameZhejiang Jingxin Pharmaceutical Co., Ltd.
Listing Date2004-07-15
Issue Price10.05RMB
Registered Capital86102.91410k RMB
Legal RepresentativeLv Gang
Registered AddressNo. 800, East Xinchang Avenue, Yulin Street, Xinchang County, Zhejiang Province
IndustryChemical Pharmaceuticals
Main BusinessResearch, development, production, and sales of chemical preparations, traditional Chinese medicine, biological preparations, chemical active pharmaceutical ingredients (APIs), and medical devices.
Company ProfileZhejiang Jingxin Pharmaceutical Co., Ltd. is a pharmaceutical listed company (Stock Code: 002020) integrating R&D, production, and sales. Currently, the company has a registered capital of 736 million yuan, total assets of 4.9 billion yuan, and net assets of 3.9 billion yuan. The company has two headquarters in Xinchang and Hangzhou, and operates five production bases: the preparation production base in Xinchang, the API production bases in Shangyu and Shangrao (Jiangxi), the traditional Chinese medicine production base in Bayannur (Inner Mongolia), and the medical device production base in Shenzhen. The company has established a Shanghai Research Institute in Zhangjiang High-Tech Park, Shanghai, with a total of over 2,500 employees.

Stock Details

1. Key Indicators

  • Total Shares(W): 86102.91
  • Circulating A-Shares(W): 72396.83
  • Earnings Per Share(RMB): 0.7000
  • Net Assets Per Share(RMB): 6.5635
  • Operating Revenue(W RMB): 304819.21
  • Total Profit(W RMB): 66491.61
  • Net Profit Attributable to Parent(W RMB): 57561.18
  • Net Profit Growth Rate(%): 0.10
  • Weighted Return on Equity(%): 10.1000
  • Operating Cash Flow Per Share(RMB): 0.7150
  • Undistributed Profit Per Share(RMB): 3.7027
  • Capital Reserve Per Share(RMB): 2.0016

2. Main Business

The main business covers:

  • Research, production, and sales of chemical preparations
  • Research, production, and sales of traditional Chinese medicine
  • Research, production, and sales of biological preparations
  • Research, production, and sales of chemical APIs
  • Research, production, and sales of medical devices

3. Company Basic Information

  • Company Name: Zhejiang Jingxin Pharmaceutical Co., Ltd.
  • Listing Date: 2004-07-15
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 800, Xinchang Avenue East, Yulin Street, Xinchang County, Zhejiang Province
  • Website: www.jingxinpharm.com
  • Company Profile: The company was established on September 29, 2001, with the approval of the Zhejiang Provincial Government Enterprise Listing Leading Group (Zhe Shang Shi [2001] No. 80). It was transformed from Zhejiang Xinchang Jingxin Pharmaceutical Co., Ltd. into a joint stock company. The company completed the industrial and commercial registration change procedures at the Zhejiang Provincial Administration for Industry and Commerce on October 25, 2001.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Jingxin Holding Group Co., Ltd. General Legal Person 13496.64 18.64
2 Shanghai International Group Asset Management Co., Ltd. General Legal Person 1230.99 1.70
3 National Social Security Fund Portfolio 110 Social Security Fund 772.75 1.07
4 Hong Kong Securities Clearing Company Ltd. Northbound Capital 745.88 1.03
5 E Fund Tahe Growth Equity Pension Product - Industrial and Commercial Bank of China Limited Asset Management Plan 664.30 0.92
6 China Merchants Prosperity Preferred Equity Securities Investment Fund Class A Fund 195.61 0.27
7 China Merchants Pioneer Securities Investment Fund Fund 159.15 0.22
8 Xinao Premium Life Mixed Securities Investment Fund Class A Fund 145.80 0.20
9 Tianhong Healthcare Mixed Securities Investment Fund Class A Fund 128.33 0.18
10 Hongtu Innovation Enhanced Return Bond Securities Investment Fund Class A Fund 105.04 0.15

5. Concept Sectors

  • Generic Drugs
  • Hepatitis Concept
  • Innovative Drugs
  • Margin Trading & Securities Lending
  • High-Performance Stocks
  • Share Buyback Plan
  • Employee Stock Ownership
  • New Social Security Fund Holdings
  • SME 300 Index
  • CSI Buyback Index

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information